VF
GALT icon

Virtu Financial’s Galectin Therapeutics GALT Stock Holding History

Virtu Financial’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55K Sell
11,940
-2,963
-20% -$7.68K ﹤0.01% 1210
2026
Q1 		$42K Sell
14,903
-38,648
-72% -$118K ﹤0.01% 1312
2025
Q4 		$223K Buy
53,551
+14,583
+37% +$76.8K 0.01% 974
2025
Q3 		$165K Buy
+38,968
New +$147K 0.01% 952
2024
Q3 		– Sell
-11,233
Closed -$25K – 1544
2024
Q2 		$25K Buy
+11,233
New +$34.1K ﹤0.01% 1003
2023
Q1 		– Sell
-39,169
Closed -$44K – 1706
2022
Q4 		$44K Buy
39,169
+26,345
+205% +$35.1K 0.01% 1107
2022
Q3 		$21K Buy
+12,824
New +$24K ﹤0.01% 1385
2022
Q2 		– Sell
-16,261
Closed -$26K – 1754
2022
Q1 		$26K Sell
16,261
-1,402
-8% -$2.71K ﹤0.01% 1260
2021
Q4 		$37K Buy
+17,663
New +$50.4K ﹤0.01% 1408
2021
Q2 		– Sell
-14,683
Closed -$32K – 1698
2021
Q1 		$32K Buy
+14,683
New +$32.9K ﹤0.01% 1476
2019
Q4 		$157K Buy
+54,738
New +$190K 0.02% 993
2018
Q4 		– Sell
-17,752
Closed -$107K – 1699
2018
Q3 		$107K Buy
+17,752
New +$97.7K 0.01% 1181

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Virtu Financial's GALT Position: Q2 2026 in Review

Virtu Financial reduced its Galectin Therapeutics (GALT) stake by 20% in Q2 2026, selling an estimated $7.68K and leaving 11,940 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #1210.

Virtu Financial first reported a position in GALT in Q3 2018 and has held it in 12 quarters since. The position peaked at $223K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Virtu Financial held 11,940 shares of Galectin Therapeutics worth $55K as of Q2 2026.
  • Virtu Financial sold 2,963 Galectin Therapeutics shares in Q2 2026, an estimated $7.68K.
  • Galectin Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1210 holding.
  • Virtu Financial first reported a position in Galectin Therapeutics in Q3 2018 and has held it in 12 quarters since.
  • Virtu Financial's Galectin Therapeutics position peaked at $223K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.